Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More

Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months

A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have been consumed.

Believed to be the first scientific research into the effects of psychedelics and sex, the new findings combine responses from nearly 300 participants who reported overall improvements after a psychedelic experience. Keep reading.

Groundbreaking: FDA Reviews MDMA Therapy For PTSD, Accepts New Drug Application

The Food and Drug Administration (FDA) has recently accepted a New Drug Application (NDA) from Lykos Therapeutics for the use of MDMA-assisted therapy in treating Post-Traumatic Stress Disorder (PTSD).

This decision marks a significant milestone in the journey toward potentially integrating psychedelic-assisted therapies into mainstream medical practice. Lykos has been at the forefront of research on this innovative treatment approach. Keep reading.

Police Seizures Of Psychedelic Mushrooms Increases, New Study Finds

Psilocybin, the psychedelic substance in “magic mushrooms,” has been featured in the media as researchers study its potential clinical applications. Two states have undertaken regulated programs for its effective use and several cities have passed decriminalization measures for a variety of natural psychedelics including these mushrooms.

Yet at the federal level, psilocybin is still illegal. Researchers analyzed data on law enforcement seizures of psychedelic mushrooms to better understand their use prevalence. Keep reading.

Canadians View Psilocybin Therapy As ‘Reasonable Medical Choice’ For End-Of-Life Distress, WA Doctor Requests DEA Approval

A majority of Canadians (79.3% ) consider psilocybin-assisted therapy to be “a reasonable medical choice” for addressing “existential distress” during the final stages of life, a team of 12 experts behind the new research revealed.

A study, published last month in the journal Palliative Care, is based on data collected from an online survey that was conducted in Canada between November 23 and December 4, 2022. Find out more.

In related news, Washington Doctor Sunil Aggarwal is suing the DEA to allow him to lawfully use psilocybin therapy with terminally ill patients. Here's the latest claim.

The Milestone Round

• Psychedelics reform picks up steam with no signs of slowing: what’s new in CA, HI, RI, AK & IN.
• MAPS, Eight Capital and Integrated V.C. back Numinus Wellness (OTC:NUMIF) $6M offering.
• Podcast: Unveiling the equivocal universe of psychedelic retreats, proficient insights from MycoMeditations.
• FDA hosts public psychedelics discussion, discloses major growth on a number of new psychiatric drugs filings post-2000.
• Magdalena Biosciences performs new research on traditional plants for modern mental health challenges.
• Psilocybin mushrooms for sale: Is it legal anywhere in America?
• Which are the strongest psychedelics out there? Brief overview, rankings and practical insights.
• A cannabis investor’s introduction to opportunities in psychedelics.

See Also: Last Week's Edition Of ‘Psyched'

Psychedelics ETF’s Weekly Performance

AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Feb. 12 at $1.44, following prior weeks’ openings at $1.42, $1.38 and $1.37 (Feb. 5, Jan. 29 and Jan. 22, respectively.)

On Friday, Feb. 9 it closed at $1.44, following prior weekly closes at $1.43, $1.43 and $1.37 (Feb. 2, Jan. 26 and Jan. 19, respectively.)

Last week’s highest was $1.47, vs. prior weekly highest at $1.60, $1.44 and $1.45.

Week’s lowest was $1.37, vs. prior weekly lowests at $1.39, $1.38 and $1.34.

Highest Trading Psychedelics Stocks Friday, Feb. 9 At Close, Prior To Earnings Reports

• COMPASS Pathways (NASDAQ:CMPS) closed at $10.33, slightly behind Feb. 2 close at $10.85 and Jan. 26 at $10.62 yet still way up from three weeks past close at $ 8.07.
• GH Research (NASDAQ:GHRS) closed at $8.04, sustaining its upper trend vs. Feb. 2 closing at $7.64, Jan. 26 at $7.25, and Jan. 19 at $5.86.
• Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $4.40, an uptake as of Feb. 2 close at $4.02, Jan. 26 at $3.70 and Jan. 19 at $3.60.
• Incannex Healthcare (NASDAQ:IXHL) closed at $3.19, down from Feb. 2 closing price at $3.22, Jan. 26 at $3.74 and Jan. 19 at $4.03.
• Bright Minds Biosciences (NASDAQ:DRUG) closed at $1.86, following Feb. 2 close at $2.18, Jan. 26 at around $1.90, and Jan. 19 at $1.93.
• Atai Life Sciences (NASDAQ:ATAI) closed at $1.73, following Feb. 2 close at $1.81, Jan. 26 at $1.72, and Jan. 19 at $1.69.
• Silo Pharma (NASDAQ:SILO) closed at near $1.52, similar to Feb. 2 close around $1.51, Jan. 26 around $1.54, and Jan. 19 at $1.38.
• Clearmind Medicine (NASDAQ:CMND) closed at $1.41, behind Feb. 2 at $1.80, Jan. 26 at $1.46, yet still higher than Jan. 19 at $1.05.
• Seelos Therapeutics (NASDAQ:SEEL) closed at $0.78, falling from prior closings on Feb. 2 ($0.88), Jan. 26 ($1.07) and Jan. 19 ($1.28.)
• Enveric Biosciences (NASDAQ:ENVB) closed at $0.77, continuing a descending trend as per Feb. 2 close at $0.83, Jan. 26 at near $0.90, and Jan. 19 at $1.09.

Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!

Also, Benzinga Cannabis Conferences are coming to Los Angeles!
Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don’t miss this chance to be at the forefront of the cannabis industry’s growth and innovation!
Join now.